PEGINESATIDE- A NOVEL ERYTHROPOIETIN MIMETIC AGENT FOR THE TREATMENT OF ANAEMIA IN CHRONIC RENAL FAILURE PATIENTSAbstract
Anaemia associated with chronic kidney disease (CKD) affects the overall health of the patients leading to increased morbidity and mortality. Erythropoietin stimulating agents (ESAs) have been the standard of care for the treatment of such patients since last 20 years. These agents have the potential to increase mean haemoglobin levels in both pre dialysis and dialysis maintenance phases hence lowering the cardiovascular complications and all-cause mortality. After epoetin and darbepoetin, Peginesatide, a novel pegylated erythropoietin (EPO) mimetic agent has recently been approved in March, 2012. Its better stability, once a month administration and non-immunogenicity makes this a preferable ESA. This review will elucidate the available evidence on efficacy and safety of this drug after analyzing various studies conducted in patients with renal anaemia. Searches of Pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like peginesatide, CKD, ESA and renal anaemia.
R. Nandha*, A. Maheshwari , K. Sekhri and S. Aditya
Assistant Professor, Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences , Sector 25, Panjab University, Chandigarh, India
31 January, 2013
12 March, 2013
19 May, 2013
01 June, 2013